Gut Microbiome Diversity Predicts Response to Dual Immunotherapy in Advanced Lung Cancer

A prospective multicenter study has identified baseline gut microbiota composition as a biologically meaningful determinant of response to dual checkpoint blockade in advanced non-small cell lung cancer (NSCLC), potentially informing the need for chemotherapy intensification. The research, published in ESMO Open in March 2026, examined patients receiving ipilimumab plus nivolumab with or without chemotherapy.

Dual immune checkpoint inhibition with ipilimumab plus nivolumab represents an established therapeutic strategy for advanced NSCLC, capable of producing durable responses even in tumors with low PD-L1 expression. However, clinical benefit remains restricted to a subset of patients, and the optimal integration of chemotherapy into dual immunotherapy regimens continues to represent a major unresolved clinical challenge.

Patients with advanced or recurrent NSCLC received either ipilimumab plus nivolumab alone or combined with chemotherapy. Baseline fecal samples underwent 16S rRNA gene sequencing to quantify microbial diversity and taxonomic composition. Parallel translational analyses incorporated multiplex immunofluorescence evaluation of tumor-infiltrating immune populations.

Across the overall cohort, the objective response rate was 44 percent, disease control rate was 63 percent, median progression-free survival was 5.8 months, and median overall survival was 24.8 months. Although addition of chemotherapy increased response rates numerically (59 percent versus 24 percent), survival differences between treatment strategies were not uniformly observed in unselected patients, underscoring biological heterogeneity beyond treatment intensity alone.

Among patients treated with ipilimumab plus nivolumab alone, high α-diversity was associated with significantly prolonged progression-free survival, increased intratumoral CD8⁺ T-cell infiltration, and enrichment of PD-1⁺CD8⁺ effector populations. Responder profiles demonstrated expansion of short-chain fatty acid-producing commensal taxa, including members of Lachnospiraceae, Eubacterium, and Agathobacter, previously implicated in immune-metabolic activation and interferon-γ–mediated cytotoxic responses.

Notably, this microbiome-outcome association disappeared when chemotherapy was added, suggesting that cytotoxic therapy may partially overcome microbiome-dependent immune resistance mechanisms.

Inverse probability-weighted analyses demonstrated that patients with low microbiome diversity derived significant progression-free survival benefit from chemo-immunotherapy, while patients with high diversity showed no clear survival advantage from chemotherapy addition. These findings support a biologically coherent model in which chemotherapy functions as an immune-restorative intervention, potentially through induction of immunogenic cell death, enhanced antigen release, and dendritic cell activation in microbiome-impaired immune environments.

Antibiotic exposure within 30 days prior to treatment initiation independently correlated with inferior progression-free survival and overall survival. Importantly, this effect occurred despite preserved global diversity indices, suggesting that functional microbial disruption rather than diversity loss alone may impair antitumor immunity.

Mechanistically, short-chain fatty acid-producing microbiota appear to enhance antitumor immunity through metabolic support of CD8⁺ T-cell function, promotion of interferon-γ–mediated cytotoxic activity, activation of NOD-like receptor signaling, and reduction of regulatory T-cell–mediated immunosuppression. Conversely, dysbiosis-associated taxa linked to intestinal inflammation were enriched among non-responders and associated with immune exhaustion phenotypes.

Current treatment selection largely relies on tumor-derived biomarkers, particularly PD-L1 expression, which incompletely captures response heterogeneity. Increasing evidence suggests that systemic host factors, particularly the gut microbiome, play a critical role in shaping antitumor immunity through modulation of T-cell activation, antigen presentation, and inflammatory signaling pathways.